Articles tagged with Brain Cancer
Researchers explore earlier genetic diagnoses, improved cancer diagnostics, and genomic tracking of a deadly mpox outbreak in children. Studies demonstrate the potential to identify inherited conditions years before symptoms appear and improve childhood cancer testing.
Scientists identify chimeric RNA molecules as essential in cellular health and disease, finding they play a wide variety of critical roles in vital cellular processes. Faulty chimeric RNA are often malfunctioning in breast cancer tumors, prompting new cancer treatments targeting specific chimeras.
A new review examines the relationship between tumors and the nervous system, suggesting that psychedelics may be able to 'listen' to the system and provide relief from cancer-related symptoms. The review also explores the potential for psychedelics to modulate the immune system and reduce inflammation in cancer patients.
Researchers propose that childhood cancers may spread aggressively by 'shape-shifting' into different cellular states, rather than accumulating genetic mutations. This process may be reversible, and understanding these transitions could lead to new treatment opportunities and potentially predict when cancers are preparing to spread
Researchers from IIT Gandhinagar explore a new attack strategy against glioblastoma, a deadly form of brain cancer. Two compounds, SPK17 and SPK17b, were found to suppress the growth of glioblastoma cells by blocking the TTK protein, making them more vulnerable to treatments like radiotherapy.
A new study reveals that aggressive brain tumors follow predictable rules, allowing for the development of targeted treatments. The research, published in Nature, used multi-omic technologies to map over one million cells across glioblastoma tumors, providing a holistic view of this cancer type.
Researchers have engineered CAR-T cells that target brain tissue, allowing them to selectively destroy tumor cells in pediatric brain cancer DMG. The new therapy, B-SYNC CAR-T, has shown promise in laboratory tests, with the cells persisting and fighting cancer for over 70 days.
Researchers at Duke University have identified SERINC2 as a critical driver of brain metastasis, a leading cause of cancer death. By promoting phosphatidylserine accumulation, SERINC2 activates AXL signaling, allowing cancer cells to invade and create new tumors in the brain.
MIT researchers have designed an implantable drug-delivery device that uses ultrasound to enhance the distribution of drug molecules in the brain. The device, called LUCID, can release drugs over an extended period and bypass the blood-brain barrier, offering a potential way to prevent the recurrence of aggressive brain tumors.
A UT San Antonio College of Sciences researcher has developed a novel molecular smart probe that illuminates breast cancer cells during surgery, providing surgeons with cleaner margins and patients lower risk of recurrence. The probe targets proteins in the cells that fuel tumor growth and is paired with an FDA-approved drug to form a ...
A 55-year-old man with glioblastoma exhibiting amplifications in MDM2 and EGFR genes underwent comprehensive genomic profiling and an international molecular tumor board. The case highlights the potential for precision oncology to identify potential treatment strategies for aggressive brain cancer.
The Phase 1b FURTHER trial revealed that firmonertinib achieved durable antitumor activity in patients with EGFR PACC-mutated non-small cell lung cancer, with 43% and 68% objective response rates at 160mg and 240mg daily doses, respectively. Patients with complete clearance of EGFR PACC mutations from their blood experienced higher res...
A recent study has identified unique genetic changes in brain tumors that recur after treatment, offering new insights into resistance to therapy. The research, conducted across 10 countries, found that different types of gliomas undergo distinct genetic changes, with some associated with poorer outcomes.
Two UCLA-led studies reveal features of effective immune responses in glioblastoma and introduce a preclinical model that more closely mirrors the human disease. Long-term survivors showed evidence of a stronger immune response within their tumors, offering important clues for developing treatments.
Researchers identified a combination treatment that reprograms myeloid cells and boosts T cells, shrinking tumors and preventing recurrence. The approach showed a 40% long-term survival rate in murine models and holds promise for other types of recalcitrant cancer.
Researchers found that stroke can reshape the tumor environment, accelerating glioma growth and spread by exploiting the brain's repair system. The study identified tumor-associated astrocytes with reduced calcium activity as a key driver of this process.
Researchers developed a mass spectrometry method to analyze tissue during brain tumor surgery, distinguishing glioma from non-tumor tissue with high confidence. The method, which takes roughly three minutes, provides actionable molecular information during surgery, potentially guiding treatment decisions and improving patient outcomes.
A Phase III trial found that delivering focused radiation therapy over three to five sessions after surgery for a large brain metastasis reduced cancer recurrence at the surgical site. Fractionated stereotactic radiosurgery also showed a trend in controlling brain metastases that had not been removed surgically. Median overall survival...
A multicenter study found that fractionated stereotactic radiosurgery reduced brain metastases recurrence and improved survival rates compared to single treatment. The approach delivered higher total doses and allowed healthy tissue to recover between treatments, while tumor cells couldn't repair.
A phase 3 trial found that delivering focused radiation therapy over three to five sessions after surgery for a large brain metastasis reduced cancer recurrence and improved survival. Patients who received multi-session treatment lived nine months longer than those treated in a single session without significantly increasing side effects.
Researchers have identified a transient phase during which metastatic seeds are particularly vulnerable to elimination using three drugs, two of which are already approved. This discovery opens a potential route to stopping the disease before it becomes clinically apparent, paving the way towards prevention and potentially preventing r...
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
Researchers developed an AI approach to predict glioblastoma recurrence, allowing for targeted treatments before the cancer becomes visible on MRI. The tool uses microscopic images of fresh, unprocessed tissue and scored based on tumor infiltration, with an accuracy of predicting recurrence within 5-10 millimeters of the sampled tissue.
Researchers are exploring biomarker-guided patient selection and combination therapies to overcome glioblastoma's biological barriers. Agents targeting tumor metabolism, immunotherapies, and oncolytic viruses are being investigated.
Researchers explored strategies to restore MHC-I expression in CNS cancers to make them more visible to the immune system. Approaches include epigenetic therapies, AAV vectors, PCSK9 inhibition, and modifying the tumor microenvironment. However, efficient delivery, antigen processing, and a limited neoantigen repertoire remain signific...
Two UCLA studies published in Cell and Science uncover the role of metabolism and physical signals in guiding radial glia to produce specific cell types in the developing human cortex. Metabolic research found that the pentose phosphate pathway influences cell fate, while thalamic projections make direct physical contact with radial gl...
A new study shows that administering cell immunotherapy before surgery to remove a brain tumour is significantly more effective than administering it afterwards. CAR-T cells were able to neutralize tumor cells and immune suppression, leading to unprecedented durable tumour control.
The researcher will investigate how infected cells live and die, and what chemical signals they release to surrounding cells. This work could lead to better antiviral drugs and virus-based cancer treatments.
A large analysis of patient outcomes shows that tumor ablation and treatment timing extend survival in patients with glioblastoma. The study identifies factors leading to the best outcomes, providing critical new information to improve therapy for these patients.
Researchers developed a new approach called SHIFTERS that uses focused ultrasound to temporarily 'light up' solid tumors, giving cancer-fighting immune cells a target they can recognize. The technology allows doctors to control where and when treatment switches on, potentially making solid tumors easier to treat.
Recent research explores the use of nanomaterial-based drug delivery to increase treatment efficacy for glioblastoma, a type of brain tumor with poor prognosis. Stimuli-responsive and biomimetic nanomedicines are designed to overcome the blood–brain barrier and deliver drugs selectively within tumors.
Researchers at USC have developed a genetic tool called the Mechano-Recorder to measure tumor cell softness. This insight can help target hard-to-reach cancer stem-like cells for destruction, potentially improving cancer treatment outcomes.
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
Researchers from Virginia Commonwealth University have uncovered a protein, TRNAU1AP, that helps glioblastoma cells survive and multiply. Targeting this protein could make cancer cells more vulnerable to treatment, potentially leading to improved survival rates.
Scientists at UVA have developed a new method to target glioblastoma, the most common and deadly brain cancer, by delivering microRNAs through the brain's natural barrier. The approach shows promise in slowing tumor growth and extending survival in animal models.
Researchers developed an AI-assisted technique to identify and treat malignant brain tumors by targeting multiple arterial pedicles. The approach successfully covered over 85% of each tumor in three patients, reducing delivery outside the intended treatment area.
Researchers at UT MD Anderson Cancer Center have made significant progress in treating rare brain infections with a virus-specific T cell therapy, achieving an overall response rate of 56.8% in patients with progressive multifocal leukoencephalopathy (PML). The center also introduced a novel CAR T cell therapy for hard-to-treat kidney ...
Sylvester researchers develop AI-powered fracture prediction models, train as wildland firefighters to reduce cancer risk, and discover new targets for pancreatic cancer treatment. A new tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells.
A multidisciplinary consensus updates treatment guidance for prolactinomas, emphasizing early recognition, individualized management strategies, and advanced imaging. The recommendations cover screening, assessment, diagnosis, treatment, and long-term monitoring to improve patient outcomes and quality of life.
Researchers identify a promising new strategy to overcome drug resistance in deadly brain cancer by blocking nitrosative stress. Combining BA-101 with temozolomide slows tumor growth, reduces cancer's ability to spread, and increases cancer cell death.
A clinical trial has shown that setmelanotide, a new drug, can achieve significant weight loss in people whose weight has become dysregulated following treatment for a brain tumor. The treatment resulted in a 20% reduction in BMI, with participants experiencing substantial health benefits.
Researchers discovered how ATRX mutations reprogram gene regulation architecture to fuel glioma growth and progression. Targeting genes downstream of ATRX slowed cancer progression in preclinical models.
Researchers developed a strategy to attack glioblastoma on two fronts by targeting the tumour and its immune support system. In preclinical models, the therapy eliminated detectable tumours and led to long-term disease-free survival.
Researchers developed an mRNA vaccine that targets neuroblastoma, delaying tumour development by 10-11 days and reducing tumour size by 70% in preclinical models. The vaccine uses peptide nanoparticles to target GPC2, a protein found on the surface of neuroblastoma cells.
Researchers found that radiation therapy not only targets tumor cells but also activates immune pathways to make tumors more receptive to immunotherapy. The study suggests that radiation-immunotherapy combination strategies could improve patient outcomes by reshaping the surrounding immune landscape and recruiting T cells.
Christina Tringides, an assistant professor at Rice University, has won the Pew Biomedical Scholar award to explore how glioblastoma grows and spreads into healthy tissue. Her research aims to develop personalized therapies for brain cancer by mimicking the brain's extracellular matrix.
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
Johanna Joyce, a leading tumor immunologist, has begun her two-year term as President of the European Association for Cancer Research. She will focus on strategic oversight, promoting broad scientific collaboration, dialogue, and training, while addressing issues such as gender disparities in science.
Researchers at UCLA Jonsson Comprehensive Cancer Center have been awarded a $3.2 million NIH grant to develop advanced imaging and surgical strategies for improving glioblastoma outcomes. The team aims to use pH-based imaging to guide precise tumor removal and explore targeted therapies that target the tumor's acid-regulating systems.
A University of Ottawa-led study has discovered a hidden network driving glioblastoma's aggressive growth, highlighting a promising target for next-generation therapies. The research reveals that a protein called OSMR plays a critical role in tumor progression and supports the survival of brain tumour stem cells.
Researchers used patient-derived xenograft (PDX) models to study deadly DNA loops in cancer cells. They found significant similarities between human tumor samples and PDX models, including consistent presence of extra copies of oncogenes. These findings suggest that ecDNA-positive tumor cells may drive tumor growth and recurrence.
Researchers used tissue samples, pathology images, and clinical data from 672 patients to train AI models to classify meningioma subtypes and predict recurrence risk. The findings suggest that AI can help clinicians obtain more detailed tumor information without requiring advanced genetic testing.
Researchers developed a nanofiber drug delivery system that uses electrospun fiber membranes to deliver multiple drugs in concert, demonstrating improved efficacy against glioblastoma. The system enables localized long-term delivery of drugs directly at the tumor site after surgery.
Researchers at MUSC Hollings Cancer Center have identified a potential way to reduce relapse in medulloblastoma by targeting tumor cells most likely to survive treatment and drive regrowth. The dual-pathway approach, focusing on CK1α, shows promise in preclinical models.
Researchers found that smaller tetraploid cancer cells are more aggressive and tumorigenic, associated with worse prognosis and lower survival rates in several cancer types. This discovery challenges the conventional understanding of tetraploidy's role in cancer progression.
A new study reveals that nitrosylcobalamin, a vitamin B12 analog, selectively crosses the blood-brain barrier and targets glioblastoma tissue, demonstrating broad antitumor activity. The therapy also shows synergistic activity with existing treatments, offering a promising new strategy for treating this deadly brain cancer.
Researchers from Mass General Brigham Cancer Institute presented various studies on cancer treatments, including the efficacy of lung cancer drug neladalkib and a psychosocial digital app for patients with multiple myeloma. An electronic frailty index was also used to identify high-risk older adults receiving CAR-T cell therapy.
Researchers from ECOG-ACRIN Cancer Research Group will present updated outcomes from the STAMP study on Merkel cell carcinoma, primary results from studies in glioblastoma and non-small cell lung cancer, and emerging approaches in precision oncology. AI-driven insights from the TAILORx breast cancer trial will also be showcased.
A new cytokine-armored CAR-T cell therapy has been developed to attack aggressive brain tumors in mice while reducing side effects. The approach recruits the body's immune system using IL-12 and DR-18 proteins, strengthening the anti-cancer response and improving tumor control.
Researchers have discovered that errors in the final step of cell division can cause dramatic changes in developing brain cells, leading to abnormalities such as multiple nuclei and cilia. The study found that a protein called p53 acts as a guardian of brain development by triggering the self-destruction of abnormal cells.